High-performance liquid chromatographic separation of an HIV-1 reverse transcriptase inhibitor and its enantiomer.
This article describes the direct separation of an HIV-1 reverse transcriptase inhibitor and its enantiomer by HPLC on a silica-bonded polyacrylamide (ChiraSpher) column. The column selection was based on specific interactions between the individual enantiomers and the chiral stationary phase. The influence of some chromatographic conditions, such as concentration of the polar modifier in the mobile phase, column flow-rate and column temperature, on column performance was investigated. The separation was applied to the determination of the minor enantiomer in the bulk drug and as low as 0.3% of minor enantiomer was detectable.
Wang
T
T
Analytical Research Department, Merck Research Laboratories, Rahway, NJ 07065-0900, USA.
Grinberg
N
N
Bicker
G
G
Tway
P
P
Thompson
K
K
D001667:Binding, Competitive; D054303:HIV Reverse Transcriptase; D015497:HIV-1 / Q000201:enzymology*; D006863:Hydrogen-Ion Concentration; D011799:Quinazolines / Q000737:chemistry / Q000302:isolation & purification* / Q000494:pharmacology; D052999:Quinazolinones; D012194:RNA-Directed DNA Polymerase / Q000187:drug effects*; D018894:Reverse Transcriptase Inhibitors / Q000737:chemistry / Q000302:isolation & purification* / Q000494:pharmacology; D012997:Solvents; D013237:Stereoisomerism; D013696:Temperature
D011799:Quinazolines; D052999:Quinazolinones; D018894:Reverse Transcriptase Inhibitors; D012997:Solvents; C091038:L 738372; D054303:HIV Reverse Transcriptase; D012194:RNA-Directed DNA Polymerase